Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bitcoin ETF (BITU) vs Sanofi SA (SNY) Price & Performance

ProShares Ultra Bitcoin ETFTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bitcoin ETF vs Sanofi SA — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.36, while Sanofi SA trades at $43.51 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while ProShares Ultra Bitcoin ETF pays none, and Sanofi SA is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

BITUSNY
Sector
Leveraged / InverseHealth
52-Week High
$64.41$52.34
52-Week Low
$8.12$41.33
Market Cap
$104.30B
Enterprise Value
$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bitcoin ETF

BITU trades at $9.64, up 1.69% with neutral technical signals. The stock shows mixed momentum with bullish moving averages but neutral oscillators. Recent dividend payments of $0.01-$0.02 provide shareholder returns, though key financial ratios remain undisclosed in current filings.

The outlook remains cautious with technical indicators showing limited directional bias. Investment opportunity exists through dividend yield, but risks include volatility and lack of clear fundamental data. Analyst sentiment appears neutral with equal buy/sell recommendations.

Sanofi SA

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bitcoin ETF

BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.

Read more on BITU

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY